You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Merck
Express Scripts
Mallinckrodt
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,604,020

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,604,020 protect, and when does it expire?

Patent 8,604,020 protects BESIVANCE and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 8,604,020
Title:Fluoroquinolone carboxylic acid molecular crystals
Abstract: Disclosed herein is a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1-cyclopropyl-8-- chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid. The molecular crystal is characterized by at least one of: (a) an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2.theta. angles of 10.6, 15, 19.7, 21.1, and 22.degree..+-.0.2.degree.; (b) a DSC melting peak at 288.degree. C.; (c) a .sup.13C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91. The compound belongs to the class of fluoroquinolones and is useful as an antibacterial agent.
Inventor(s): King, Jr.; Harry M. (Webster, NY)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:13/826,469
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,604,020

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,604,020

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 075926   Start Trial
Brazil PI1009849   Start Trial
Canada 2756769   Start Trial
China 102369189   Start Trial
European Patent Office 2411369   Start Trial
Japan 2012521433   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.